Bhat Vishalakshi, D'Souza Palmeera, Shah Parag K, Narendran V
Department of Pediatric Retina and Ocular Oncology, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Coimbatore, Tamil Nadu, India.
Middle East Afr J Ophthalmol. 2016 Apr-Jun;23(2):208-11. doi: 10.4103/0974-9233.175895.
To review the surgical outcomes of intravitreal bevacizumab (IVB) along with subretinal fluid drainage with cryotherapy in patients with stage 3B Coats' disease.
A retrospective study of seven cases of stage 3B Coats' disease, who underwent subretinal fluid drainage with cryopexy, from May 2011 to March 2014. Five eyes received additional IVB at the end of surgery. Green laser therapy was performed on telangiectatic vessels postoperatively.
The mean age was 34 months (range, 10-84 months). Mean follow-up was 19 months. Six patients (85.7%) had an attached retina at final follow-up. Three out of four patients (75%) that received IVB developed tractional retinal detachments (TRDs). Two eyes that did not receive bevacizumab did not develop any traction. None progressed to neovascular glaucoma or phthisis bulbi.
Simultaneous injection of bevacizumab along with subretinal drainage and cryotherapy for advanced Coats' disease could not avoid TRD.
回顾玻璃体内注射贝伐单抗（IVB）联合视网膜下液引流及冷冻疗法治疗3B期科茨病患者的手术效果。
对2011年5月至2014年3月期间接受视网膜下液引流及冷冻治疗的7例3B期科茨病患者进行回顾性研究。5只眼在手术结束时额外接受了IVB治疗。术后对扩张的血管进行了绿色激光治疗。
平均年龄为34个月（范围10 - 84个月）。平均随访时间为19个月。6例患者（85.7%）在末次随访时视网膜复位。接受IVB治疗的4例患者中有3例（75%）发生了牵拉性视网膜脱离（TRD）。未接受贝伐单抗治疗的2只眼未出现任何牵拉。无一例进展为新生血管性青光眼或眼球痨。
对于晚期科茨病，同时注射贝伐单抗联合视网膜下引流及冷冻疗法无法避免TRD的发生。
Zotero 插件